JPH0320222A - 脳内虚血症治療剤 - Google Patents

脳内虚血症治療剤

Info

Publication number
JPH0320222A
JPH0320222A JP2141755A JP14175590A JPH0320222A JP H0320222 A JPH0320222 A JP H0320222A JP 2141755 A JP2141755 A JP 2141755A JP 14175590 A JP14175590 A JP 14175590A JP H0320222 A JPH0320222 A JP H0320222A
Authority
JP
Japan
Prior art keywords
disease
agent according
brain
ischemia
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2141755A
Other languages
English (en)
Japanese (ja)
Inventor
Christopher G Boissard
クリストフアー　ジー　ボイサード
Duncan P Taylor
ダンカン　ピー　テイラー
Michael S Eison
マイケル　エス　エイソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JPH0320222A publication Critical patent/JPH0320222A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2141755A 1989-06-01 1990-06-01 脳内虚血症治療剤 Pending JPH0320222A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/360,658 US5055470A (en) 1989-06-01 1989-06-01 Method of treatment of ischemia in brain
US360658 1989-06-01

Publications (1)

Publication Number Publication Date
JPH0320222A true JPH0320222A (ja) 1991-01-29

Family

ID=23418925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2141755A Pending JPH0320222A (ja) 1989-06-01 1990-06-01 脳内虚血症治療剤

Country Status (8)

Country Link
US (1) US5055470A (enExample)
EP (1) EP0410114A3 (enExample)
JP (1) JPH0320222A (enExample)
KR (1) KR910000151A (enExample)
CA (1) CA2017781A1 (enExample)
HU (1) HU205856B (enExample)
IL (1) IL94525A0 (enExample)
TW (1) TW198681B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500757A (ja) * 2003-06-12 2007-01-18 株式会社エムズサイエンス 神経再生及び機能回復のためのシグマリガンド
JP2009516650A (ja) * 2005-11-01 2009-04-23 株式会社エムズサイエンス 神経再生及び機能回復のためのシグマリガンド

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
CA2081062A1 (en) * 1991-10-24 1993-04-25 Frank D. Yocca Treatment of anxiety in benzodiazepine-withdrawn patients
DE4219973A1 (de) * 1992-06-19 1993-12-23 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
KR100304017B1 (ko) * 1992-06-22 2001-11-22 추후제출 글리신수용체길항물질및이의용도
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
ES2584509T3 (es) 2007-08-21 2016-09-28 Midwestern University Composiciones para el tratamiento del ictus o accidente cerebrovascular con un agonista del receptor de endotelina B
PL2424529T3 (pl) 2009-04-30 2017-06-30 Midwestern University Nowe postępowania terapeutyczne z zastosowaniem centakwiny
US10561704B2 (en) 2013-07-08 2020-02-18 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500757A (ja) * 2003-06-12 2007-01-18 株式会社エムズサイエンス 神経再生及び機能回復のためのシグマリガンド
JP2009516650A (ja) * 2005-11-01 2009-04-23 株式会社エムズサイエンス 神経再生及び機能回復のためのシグマリガンド

Also Published As

Publication number Publication date
HUT54050A (en) 1991-01-28
CA2017781A1 (en) 1990-12-01
EP0410114A3 (en) 1992-01-02
KR910000151A (ko) 1991-01-29
HU903291D0 (en) 1990-10-28
TW198681B (enExample) 1993-01-21
EP0410114A2 (en) 1991-01-30
HU205856B (en) 1992-07-28
US5055470A (en) 1991-10-08
IL94525A0 (en) 1991-03-10

Similar Documents

Publication Publication Date Title
DE3873879T2 (de) Nicht-sedative antihistaminica enthaltende husten-/schnupfenmittel.
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
JPH0320222A (ja) 脳内虚血症治療剤
JPS59112948A (ja) コレステロ−ルレベル低下剤
JPH0157093B2 (enExample)
JPH07505646A (ja) 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト
CZ285633B6 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
EP0689437B1 (en) Use of granisetron for the treatment of post-operative nausea and vomiting
US20120122919A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
DE68908485T2 (de) Verwendung von 5-HT1A Agonisten zur Herstellung eines Arzneimittels, das gegen ischämische Verletzungen Schützt.
UA123780C2 (uk) Лікування екземи кистей
AU2008322739C1 (en) Use of anti-bacterial compounds having an anaesthetic effect
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
JP2008100924A (ja) 総合感冒薬組み合わせ製剤
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
JP3150642B2 (ja) 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
JP5386476B2 (ja) 頭蓋外傷の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシド−４−ピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
JPS60500016A (ja) 鎮痛薬組成物類
US6784194B2 (en) Therapeutic use of a thienylcyclohexylamine derivative
WO1998038997A1 (en) Use of levobupivacaine in combination with opiods or alfa2-agonists for providing anaesthesia or analgesia
HU226805B1 (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
JP2003504396A (ja) マクロライド化合物の新規用途
CA2117430A1 (en) Brofaromine as an agent for treating post-traumatic stress
CN1084622C (zh) 药物
GB2282759A (en) Use of acyclovir in treatment of post-herpetic neuralgia